ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03134872
Recruitment Status : Recruiting
First Posted : May 1, 2017
Last Update Posted : May 11, 2018
Sponsor:
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is a randomized,Phase III, multicenter ,open-label study designed to evaluate the safety and efficacy of SHR-1210 with carboplatin and pemetrexed versus carboplatin-pemetrexed in subjects who are chemotherapy naive and have Stage IIIB/IV non-squamous NSCLC.

The primary hypothesis is that SHR-1210 combined with carboplatin and pemetrexed prolongs Progression Free Survival (PFS) in per RECIST 1.1 by blinded independent central review (ITT population and population was indicated by high PD-L1 expression) compared to carboplatin and pemetrexed treatment .


Condition or disease Intervention/treatment Phase
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Disease Neoplasms by Site Neoplasm, Bronchial Carcinoma, Bronchogenic Biological: SHR-1210 Drug: Carboplatin Drug: Pemetrexed Phase 3

Detailed Description:

In this study, subjects will be randomly assigned to receive either carboplatin and pemetrexed for 4-6 cycles followed by pemetrexed maintenance until progression or unacceptable toxicity, OR receive SHR-1210 combined with carboplatin and pemetrexed chemotherapy for 4-6 cycles followed by pemetrexed maintenance with SHR-1210 until progression or unacceptable toxicity (SHR-1210 for a maximum of 2 years).

Subjects assigned to the chemotherapy arm will have the opportunity to crossover to receive SHR-1210 monotherapy once they experience progression of disease (PD) defined by RECIST 1.1 and meet all the crossover criteria.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 412 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer
Actual Study Start Date : May 22, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : June 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SHR-1210+Chemotherapy
Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
Biological: SHR-1210
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Drug: Carboplatin
Carboplatin

Drug: Pemetrexed
Pemetrexed

Active Comparator: Chemotherapy
Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
Drug: Carboplatin
Carboplatin

Drug: Pemetrexed
Pemetrexed




Primary Outcome Measures :
  1. Progression-Free Survival in the intent-to-treat (ITT) population [ Time Frame: up to 24 months ]
    PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment.

  2. Progression-Free Survival in the PD-L1-selected population [ Time Frame: up to 24 months ]
    PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment.


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: up to 24 months ]
    Determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.

  2. Duration of Response Rate(DoR) [ Time Frame: up to 24 months ]
    Determined using RECIST v1.1 criteria

  3. Time To Progression (TTP) [ Time Frame: up to 24 months ]
    Determined using RECIST v1.1 criteria

  4. Disease Control Rate (DCR) [ Time Frame: up to 24 months ]
    Determined using RECIST v1.1 criteria

  5. Overall Survival [ Time Frame: up to 24 months ]
    OS, defined as the time from randomization to death from any cause.

  6. Change from baseline in patient reported lung cancer symptoms [ Time Frame: up to 24 months ]
    Defined as time from randomization to deterioration (10 point change) on each of the EORTC QLQ-C30 and EORTC QLQ-LC13 symptom subscales (cough, dyspnea [single item and multi item subscales], chest pain, arm/shoulder pain, or fatigue) maintained for two assessments or one assessment followed by death from any cause within 3 weeks.

  7. Number of Subjects with treatment-related adverse events (AEs) [ Time Frame: up to 24 months ]
    Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Subjects who are chemotherapy naive and have Stage IIIB-IV non-squamous NSCLC.
  • 2. Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.
  • 3. Fresh cutting or ≤6 months preservation specimens must be provided.
  • 4. No prior systemic treatment. Subjects who have received prior neo-adjuvant, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 12 months from randomization since the last chemotherapy cycle.
  • 5. Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria;
  • 6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
  • 7. Have a life expectancy of at least 3 months.
  • 8. All baseline laboratory requirements will be assessed and should be obtained within 14 days prior to the first administration of study treatment.
  • 9. Female Subjects of childbearing potential must have a negative serum pregnancy test within 3 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 180 days after the last dose of study treatment.
  • 10. Male Subjects with a female partner(s) of child-bearing potential must be willing to use very efficient barrier methods of contraception for the course of the study through 180 days after the last dose of study treatment.
  • 11. Subjects has voluntarily agreed to participate by giving written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research.

Exclusion Criteria:

  • 1. Target Disease Exceptions

    1. Subjects with predominantly squamous cell histology NSCLC, or SCLC.
    2. Subjects with epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) translocation.
    3. Subjects with no measurable disease by CT or MRI per RECIST 1.1 criteria.
    4. Subjects with carcinomatous meningitis, or symptoms of spinal cord compression.
    5. Subjects with active CNS metastases are excluded.
    6. Subjects who can receive surgical resection or radical radiotherapy.
    7. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • 2. Medical History and Concurrent Diseases

    1. Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.
    2. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
    3. Prior therapy with systemic immunostimulatory agents within 1 months of the first dose of trial treatment.
    4. Subjects are currently participating and receiving study therapy or had participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 half-value period life of the agent, before the first dose of trial treatment.
    5. Subjects who expected to require any other form of antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC).
    6. Subjects received major surgery or radiation therapy of > 30 Gy not to chest within 4 weeks of the first dose of study treatment, or radiation therapy of > 30 Gy to chest within 24 weeks of the first dose of study treatment, or radiation therapy of < 30 Gy to chest within 2 weeks of the first dose of study treatment, and had not recovered from the toxicity and/or complications of the most recent prior chemotherapy to Grade 1 or less (except alopecia or fatigue).
    7. Subjects with a history of interstitial lung disease, or other disease may interfere with the detection or treatment of suspected drug-related lung toxicity.
    8. Other active malignancy requiring concurrent intervention.
    9. Subjects with previous malignancies (except non-melanoma skin cancers, and thefollowing in situ cancers: bladder, endometrial, cervical/dysplasia) are excluded unless a complete remission was achieved at least 5 years prior to study entry.
    10. Subjects with clinically significant cardiovascular and cerebrovascular diseases.
    11. Subjects with active pulmonary tuberculosis.
    12. Subjects have severe infections within 4 weeks of the first dose of study treatment.
    13. Subjects had or plan to have allogeneic bone marrow transplantation or solid organ transplant.
    14. Subjects had administration of a live, attenuated vaccine within 30 days of the first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study.
    15. Subjects with contraindications to platinum therapy.
  • 3. Physical and Laboratory Test Findings

    1. Known history of testing positive for human immunodeficiency virus (HIV) or
    2. known acquired immunodeficiency syndrome (AIDS).
    3. Known history of active Hepatitis B or C.
    4. Subjects with severe pleural effusion, pericardial effusion, or ascites need repeated drainage.
  • 4. History of severe hypersensitivity reactions to other monoclonal antibodies, or intravenous infusion, or carboplatin, or pemetrexed.
  • 5. Subjects have known psychiatric or substance abuse disorder (including alcohol\smoking), or be regular user (including "recreational use") of any illicit drugs that would interfere with cooperation with the requirements of the trial.
  • 6. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03134872


Contacts
Contact: Xiaoyan Kang, MD 021-60453139 kangxiaoyan@shhrp.com
Contact: Shu Wang, BA 021-60453192 wangshu@hrs.com.cn

Locations
China, Shanghai
Tongji University, Shanghai Pulmonary Hospital Recruiting
Shanghai, Shanghai, China, 200433
Contact: Caicun Zhou, MD,PhD    86-021-65115006 ext 3050    caicunzhoudr@126.com   
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Investigators
Study Director: Xiaoyan Kang, MD Jiangsu HengRui Medicine Co., Ltd.

Responsible Party: Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT03134872     History of Changes
Other Study ID Numbers: SHR-1210-III-303-NSCLC
First Posted: May 1, 2017    Key Record Dates
Last Update Posted: May 11, 2018
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:
PD-1
PD-L1
SHR-1210
Carboplatin
Pemetrexed

Additional relevant MeSH terms:
Carcinoma
Neoplasms
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Respiratory Tract Diseases
Neoplasms by Site
Thoracic Neoplasms
Respiratory Tract Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Bronchial Diseases
Carboplatin
Pemetrexed
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors